Medical Oncologist #GUcancer / Oncogeneticist / GU Y-ECI secretary @EORTC / Past fellow in GU oncology @gustaveroussy / Triathlon passionate
worldwide
Joined January 2020
- Tweets108
- Following260
- Followers72
- Likes748
Guillaume Grs retweeted
Excited to share our new @EORTC publication in European Urology describing the design of the EORTC 2238 DE-ESCALATE trial.
Can intermittent maximal androgen blockade reduce treatment burden while maintaining outcomes in selected men with #mHSPC receiving ADT + ARPI? That's the question we're addressing.
👉 doi.org/10.1016/j.eururo.202…
@DeEscalate_EU #ProstateCancer #ClinicalTrials #EUrology
Guillaume Grs retweeted
🧪 This Bladder Cancer Awareness Month, discover STARBURST 1 (EORTC-2418), advancing precision research in muscle-invasive bladder cancer under the SPECTA platform.
Many thanks to the supporters contributing to this important research.
#EORTCgenitourinary #BladderCancer
Guillaume Grs retweeted
EORTC GUCG 2238 – DE-ESCALATE: A pragmatic trial to revisit intermittent ADT in #mHSPC in the era of new ARPIs. Presentation by @fabioturco92. #ASCO26 written coverage by @zklaassen_md > bit.ly/4veWaVI @ASCO
Guillaume Grs retweeted
DE-ESCALATE (@EORTC): A pragmatic trial to revisit intermittent ADT in mHSPC in the era of new ARPIs @urotoday #ASCO26
🌟n=1,600
🌟Key elig criteria: mHSPC pts, PSA ≤ 0.2 at 6-12 mos after Rx start
🌟2:1 randomization to cMAB vs iMAB
🌟Co-primary EPs: (i) feasibility (ii) overall survival
🌟Status: May 1, 2026: 211 pts enrolled
Guillaume Grs retweeted
EORTC GUCG 2238 de-escalate: A pragmatic trial to revisit intermittent ADT in metastatic hormone-naïve #ProstateCancer in the era of new AR pathway inhibitors. Presentation by @GGrisay. #ESMO25 written coverage by @zklaassen_md > bit.ly/4qj2uda @myESMO
Guillaume Grs retweeted
🌟Challenges in Defining Clinical CR to Systemic Therapy in MIBC🌟
@EORTC #STARBURST project
🖋️ Alexandra Masson-Lecomte @AFUrology, Guillaume Grisay, @vandamme_jvd, @Achard_Verane , @LAUrology_NL, @robert_huddart, @frasor86, @LDyrskjot, Yves Allory @institut_curie, @BertrandTOMBAL, @VPanebiancoIT, @y_loriot.
@OncoAlert @EUplatinum
sciencedirect.com/science/ar…
🔸 Clinical CR ≠ Pathologic CR — current methods often fail to predict true response
🔸 STARBURST trial aims to refine cCR definition via:
• Multiparametric MRI
• Cystoscopy + urine cytology
• ctDNA (plasma & urine)
• Urinary biomarkers
🔸 Goal: tailor organ-sparing strategies and avoid overtreatment
🔸 Collaborative European effort to shape the future of MIBC response assessment
#BladderCancer #MIBC #Immunotherapy #ctDNA #PrecisionMedicine #EORTC #UroOncology #ClinicalTrials #CRvspCR #OrganPreservation #Cancer #Oncology #MedX
🚨 Defining clinical response to neoadjuvant CT in bladder is crucial to offer bladder-sparing strategies in complete or near cplt responders ! EORTC Starbust-1 will launch soon
@amassonlecomte @EORTC
@y_loriot @BertrandTOMBAL @Achard_Verane @vandamme_jvd
sciencedirect.com/science/ar…
Had the pleasure of presenting a poster of EORTC2418 - STARBURST1 at #GU25 ! It's vital to validate a clinical multimodal signature of response to NAT in MIBC ! Alexandra Masson-Lecomte @Achard_Verane
@vandamme_jvd @BertrandTOMBAL @y_loriot @EORTC
Guillaume Grs retweeted
Check out our free 20-minute webinar with a multidisciplinary panel of experts discussing the most recent data from clinical trials, treatment (de)escalation, and the role of ultra-low PSA in #mHSPC
Register for free at library.mirrorsmed.org/?utm_…
@vandamme_jvd @OncoAlert #GU #ProstateCancer
Thank you #EMUC24 for giving me the opportunity to talk about the management of mCRPC patients
mHSPC patient with profound PSA response : panel would propose de-escalation therapy ! #EMUC2024 @BertrandTOMBAL @Silke_Gillessen @fabioturco92
Guillaume Grs retweeted
Nice talk by Dr Masson-Lecomte on the importance of defining the response to NAT, as well as the importance of multimodal assessment. Question will be answered by the EORTC2418 - ‘STARBURST’ study !#EORTC #EMUC24 @y_loriot @Achard_Verane @vandamme_jvd @GGrisay @BertrandTOMBAL
Guillaume Grs retweeted
#NOVEMBREAUMASCULIN - Conférence de presse en cours pour présenter cette 2e édition du Mois de la Santé Masculine 🔵
@delataillealex #Santemasculine #BrisonsLesTabous 🚹
🚨 Excellent talk on germline testing in PC by Heather H. Cheng🚨
✅ It matters for patients AND families
✅ Germline alt. are FREQUENT and have consequences for patients
🧬Tumor-only sequencing failed to detect > 20% of pathogenic variants ⚠
@APCCC_Lugano @OncoAlert #APCCC24
Guillaume Grs retweeted
95% of @APCCC_Lugano Panellists DO NOT recommend ARPI switch for mCRPC. Yet why do investigators (many of them Panellists) and FDA approve this as control arm for trials?? “Unethical” says @AnthonyMJoshua from the floor, as did @VPrasadMDMPH on GU Cast @gu_onc #APCCC24
